Skip to main content

December 2016

 

 

academics

 

Clinical research courses

Job Opening in Comed for posts of Zonal Sales Manager, Regional Sales Manager, Divisonal Sales Manager, MR

Comed was in 1986, when a team of experienced and energetic Pharma professionals decided to go big and to do something different and better than routine. A seed was sown: a beginning was made. These young, dynamic and experienced future leaders chose Baroda (Now called Vadodara), the Educational and Pharma capital of Gujarat (Western India) as their base, a choice which itself proved to be big contributing factor for growth.

Work as Regulatory Affairs Specialist @ PPD Pharmaceuticals

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 32 countries and more than 9,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients

Post: Regulatory Affairs Specialist

Job opening in MERCK India for the post of Scientist

Merck Limited (formerly E. Merck Limited) was set up in India as the first Merck subsidiary in Asia in 1967. The Company operates both its Pharmaceuticals and Chemicals businesses in the country.
Merck was also the first Merck Group Company to go public in the year 1981.  The Merck Group now holds 51% of the share capital in Merck Limited, while the remaining 49% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.  Merck Specialities Pvt. Ltd., the wholly owned Indian subsidiary of Merck KGaA, was incorporated in 2005.

Post: Scientist-New and Emerging Science & Technologies

Work in Johnson & Johnson as Officer QA

Johnson & Johnson is the world’s most comprehensive and broadly based manufacturer of health care products. The organization is comprised of more than 250 operating companies with over 128,000 employees located in some 60 countries. With Global sales of USD 67.2 billion in 2012, Johnson & Johnson is recognized as one of the most admired and respected companies in the world.  In India, Johnson & Johnson operates as a single legal entity and consists of the 3 strategic business units: Consumer Products, Pharmaceuticals and Medical Devices & Diagnostics, which are independently managed and report into their respective Global business segments.  Ethicon Endo-Surgery is part of the Johnson & Johnson Family of Companies. We not only represent a history of innovation, but a rich tradition of patient care that begins with our parent company, Johnson & Johnson.

Post : Officer QA

Career Opportunity as Outsourcing and Contract Manager at Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. 

Post: Outsourcing and Contract Manager

Substantiating Cosmetics Product Claims

ABOUT AUTHOR
Vinay Kumar Singh.
Chief Research Officer
Parammount Cosmetics India Limited,
Bangalor, Karnataka
vinay@parammount.com

The success of a product in Today’s market place is less a function of the product performance and more a function of how it is promoted to the public. Although the cosmetic industry appears to be dominated by marketing agents, chemists play a key role in supporting their company in its choice of claims used in product promotion

Novartis announced the signing of an exclusive option, collaboration and license agreement with Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease. This agreement will enable Novartis and Conatus to jointly develop emricasan. Emricasan is an investigational, first-in-class, oral, pan-caspase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. This collaboration has the potential to expand treatment options for people in various stages of fatty liver disease, where no approved medicines currently exist.

Novartis has entered into a definitive agreement for the acquisition of Encore Vision, Inc., a privately-held company in Fort Worth, Texas, USA, focused on the development of a novel treatment in presbyopia. This acquisition would add a first-in-class disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline, providing a potentially disruptive innovation to patients in a new therapeutic area of high unmet need and high prevalence. The transaction is subject to customary closing conditions, including regulatory approval. The financial details of this transaction are not disclosed.

Vernalis plc and Tris Pharma, Inc. are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-08 New Drug Application ("NDA") for full review. This triggers a milestone payment from Vernalis to Tris. The FDA has set a Prescription Drug User Fee Act ("PDUFA") target date for conclusion of its review of 4 August 2017.

Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, has received final approval for its Abbreviated New Drug Application (ANDA) for Fenofibrate Tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA).